← Back to Search

REDUCE-BP Intervention for High Blood Pressure (REDUCE-BP Trial)

N/A
Waitlist Available
Led By Niteesh K Choudhry, MD, PhD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether a multicomponent intervention targeting providers and leveraging health information technology can reduce health disparities in racial and ethnic minorities.

Who is the study for?
This trial is for adults aged 18-85 with uncontrolled high blood pressure, who have seen their primary care physician at least once in the past two years and have a hypertension diagnosis recorded. It's focused on patients using the EPIC EHR system.
What is being tested?
The REDUCE-BP Intervention aims to help doctors manage high blood pressure better using enhanced tools within the electronic health record (EHR) system. This includes new dashboards, decision support, and improved patient communication methods.
What are the potential side effects?
Since this intervention involves non-medical changes to how doctors use EHR systems, there are no direct medical side effects associated with it. However, any change in treatment resulting from improved management may carry its own risks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in systolic blood pressure
Secondary study objectives
Change in diastolic blood pressure
Percentage of patients with guideline-concordant medications
Percentage of patients with intensification of medication
+2 more
Other study objectives
Clinical encounters

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention ArmExperimental Treatment1 Intervention
Providers within the clinics randomized to the intervention arm will receive a variety of EHR-based tools for eligible patients with uncontrolled hypertension.
Group II: Control ArmActive Control1 Intervention
Providers within the clinics randomized to usual care will receive no EHR tools, except those currently available in clinical practice.

Find a Location

Who is running the clinical trial?

National Institute on Minority Health and Health Disparities (NIMHD)NIH
429 Previous Clinical Trials
1,354,005 Total Patients Enrolled
36 Trials studying Hypertension
15,328 Patients Enrolled for Hypertension
Brigham and Women's HospitalLead Sponsor
1,664 Previous Clinical Trials
11,817,870 Total Patients Enrolled
70 Trials studying Hypertension
1,472,980 Patients Enrolled for Hypertension
Niteesh K Choudhry, MD, PhDPrincipal InvestigatorBrigham and Women's Hospital
11 Previous Clinical Trials
305,346 Total Patients Enrolled
2 Trials studying Hypertension
4,491 Patients Enrolled for Hypertension

Media Library

REDUCE-BP Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05030467 — N/A
Hypertension Research Study Groups: Intervention Arm, Control Arm
Hypertension Clinical Trial 2023: REDUCE-BP Intervention Highlights & Side Effects. Trial Name: NCT05030467 — N/A
REDUCE-BP Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05030467 — N/A
~4890 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top